Krystal Historical Income Statement
| KRYS Stock | USD 182.29 4.19 2.35% |
Historical analysis of Krystal Biotech income statement accounts such as Interest Expense of 0.0 can show how well Krystal Biotech performed in making a profits. Evaluating Krystal Biotech income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Krystal Biotech's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Krystal Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Krystal Biotech is a good buy for the upcoming year.
Krystal |
About Krystal Income Statement Analysis
Krystal Biotech Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Krystal Biotech shareholders. The income statement also shows Krystal investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Krystal Biotech Income Statement Chart
Add Fundamental
Cost Of Revenue
Cost of Revenue is found on Krystal Biotech income statement and represents the costs associated with goods and services Krystal Biotech provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Krystal Biotech's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Krystal Biotech current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.At this time, Krystal Biotech's Research Development is comparatively stable compared to the past year. EBITDA is likely to gain to about 18.8 M in 2024, despite the fact that Operating Income is likely to grow to (104.2 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 2.8M | 4.1M | 5.0M | 5.3M | Interest Income | 197K | 5.2M | 22.6M | 23.8M |
Krystal Biotech income statement Correlations
Click cells to compare fundamentals
Krystal Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Krystal Biotech income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | 3.0M | 832K | (1.3M) | 5.2M | 22.6M | 23.8M | |
| Interest Income | 3.0M | 832K | 197K | 5.2M | 22.6M | 23.8M | |
| Depreciation And Amortization | 748K | 1.9M | 2.8M | 4.1M | 5.0M | 5.3M | |
| Interest Expense | 3.1M | 1.0M | 0.0 | 832K | 1.5M | 5.2M | |
| Selling General Administrative | 6.5M | 15.1M | 40.4M | 77.7M | 98.4M | 103.3M | |
| Gross Profit | (974K) | (1.9M) | (2.8M) | (4.1M) | 47.6M | 50.0M | |
| Other Operating Expenses | 22.1M | 33.0M | 68.3M | 120.2M | 160.4M | 168.4M | |
| Operating Income | (22.1M) | (33.0M) | (68.3M) | (145.2M) | (109.7M) | (104.2M) | |
| Net Income From Continuing Ops | (19.1M) | (33.0M) | (69.6M) | (140.0M) | 10.9M | 11.5M | |
| Ebit | (22.1M) | (32.2M) | (68.1M) | (149.3M) | 12.9M | 13.5M | |
| Research Development | 15.6M | 17.9M | 27.9M | 42.5M | 46.4M | 48.8M | |
| Ebitda | (21.3M) | (30.3M) | (65.3M) | (145.2M) | 17.9M | 18.8M | |
| Cost Of Revenue | 974K | 1.9M | 2.8M | 4.1M | 3.1M | 1.8M | |
| Total Operating Expenses | 22.1M | 33.0M | 68.3M | 120.2M | 160.4M | 168.4M | |
| Income Before Tax | (19.1M) | (32.2M) | (69.6M) | (140.0M) | 12.9M | 13.5M | |
| Total Other Income Expense Net | 3.0M | 832K | (1.3M) | 5.2M | 122.6M | 128.8M | |
| Net Income Applicable To Common Shares | (19.1M) | (32.2M) | (69.6M) | (140.0M) | (126.0M) | (119.7M) | |
| Net Income | (19.1M) | (32.2M) | (69.6M) | (140.0M) | 10.9M | 11.5M | |
| Income Tax Expense | (3.0M) | 1.6M | 2.7M | 34.0M | 2.0M | 1.9M | |
| Reconciled Depreciation | 748K | 1.9M | 2.8M | 4.1M | 5.0M | 5.3M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.